ARTICLE | Clinical News
Dinutuximab regulatory update
August 24, 2015 7:00 AM UTC
The European Commission approved Unituxin dinutuximab from United Therapeutics to treat high-risk neuroblastoma in patients ages 12 months to 17 years. Specifically, it is indicated in combination wit...